Antiphospholipid syndrome (APIS) is characterized by thrombocytopenia, thromboembolic phenomena, and recurrent fetal loss, associated with anticardiolipin antibodies (ACA) and/or lupus anticoagulant. The syndrome may be primary or may be associated with other conditions such as systemic lupus erythematosus.
Introduction
Primary antiphospholipid syndrome (PAPS)' is characterized by the presence of anticardiolipin antibodies (ACA) or other antiphospholipid antibodies and/or lupus anticoagulant, thrombocytopenia, recurrent thromboembolic phenomena, recurrent fetal loss, and other diverse manifestations (1) (2) (3) (4) (5) (6) . Recently, we (6) and others (7) have shown the pathogenetic role Receivedfor publication 6 August 1991 and in revisedform 5 November 1991.
1. Abbreviations used in this paper: ACA, anticardiolipin antibodies; APLS, antiphospholipid syndrome; APTT, activated partial thromboplastin; H-3, human ACA; KCT, kaolin clotting time; PAF, platelet-activating factor; PAPS, primary antiphospholipid syndrome; TBS, Tris base buffered saline. of the ACA, by inducing an experimental model of antiphospholipid syndrome (APLS) in naive mice following passive transfer of human and mouse monoclonal and polyclonal ACA to the tail vein of BALB/c and ICR mice (7) . The APLS was exemplified by serological markers (ACA, prolonged activated partial thromboplastin time [APTT] ), hematological findings (thrombocytopenia), and clinical manifestations (recurrent fetal resorptions-the equivalent of human fetal loss and smaller fetuses and placentae).
The aim ofthe present study was to report on the induction ofPAPS by active immunization with a human ACA (H-3) (8) . This model is analogous to our experiments on the induction of systemic lupus erythematosus (SLE) in mice using human anti-DNA antibody (9, 10) .
Methods
Mice. BALB/c mice (8-10-wk old females) were purchased from the Sackler School of Medicine, Tel-Aviv University.
Antibodies. H-3 is a human monoclonal IgM (8) , generated following fusion ofperipheral blood lymphocytes ofa healthy subject immunized with diphtheria and tetanus, with GM 4672 lymphoblastoid cell line (8, 9) . The antibody binds to tetanus and diphtheria toxoids, cardiolipin, phosphatidylethanolamine, and phosphatidylserine (8) Detection of anti-ds-DNA. Anti-ds-DNA antibodies were determined according to Shoenfeld et al. (9) . Briefly, polystyrene plates with 96 flat bottom wells (Nunc) were coated sequentially with poly-L-lysine (50 ,ug/ml in water), ds-DNA-2.5 ,g/ml TBS (Tris base buffered saline) and poly-L-glutamate (50 jg/ml). Washing between steps was performed usingTBSwith 0.05% Tween-20, to minimize nonspecific bind-Determination ofanti-human JgM and anti-H-3 antibodies. ELISA plates were coated overnight with 2 Mg/ml of IgM or H-3 in NaHCO3, pH 9.6. Blocking was carried out by incubating with PBS and 0.5% gelatin. The rest of the procedure was carried out as above.
Inhibition ofanticardiolipin and anti-ds-DNA binding. Sera at the dilution giving 50% of maximal binding to the antigen in question, were preincubated with the antigen, at different concentrations (100 Mg/ml-0. 1 gg/ml). The preincubation was carried out with cardiolipin, ds-DNA or a nonrelevant protein (BSA), in order to confirm the specific binding, or to show cross-reactivity of antibodies.
After incubation of the sera with the different inhibitors (DNA, cardiolipin) overnight at 40C, the remaining activity was tested by ELISA as detailed above. As control we used the serum incubated without the antigen, but with the appropriate volume of PBS instead. The percentage of inhibition was calculated as follows:
Inhibition ofserum binding to cardiolipin with platelets. Preincubation of sera from the immunized mice with different concentrations of fresh platelets was carried out in a tube for 18 h. Cell concentration ranging from 2 x 106 to 1.25 X 109/ml of diluted sera (1:400) were incubated for 18 h. Platelets were precipitated using high speed centrifugation. The remaining binding to cardiolipin and other antigens was determined using direct binding to antigen-coated plates as described above.
Inhibition ofserum binding to platelets with cardiolipin. Binding to platelets was assessed using an ELISA technique. ELISA plates were coated with 1 x 106 platelets in 100 Ml of PBS. Coating was performed overnight in 4°C. After washing, free binding sites were blocked using 1% BSA in PBS. Sera preincubated for 2 h with different concentrations of either cardiolipin or BSA were added to the plates. Excess binding was determined using anti-mouse IgG or IgM conjugated to alkaline-phosphatase.
Binding ofserum immunoglobulin to platelet membrane proteins. The binding of serum immunoglobulin to platelet membrane proteins was analyzed employing the immunoprecipitation assay detailed by Coller et al. (1 1) .
Bloodcell counts. White blood cell and platelet counts from individual blood samples were quantified in diluted blood using a single optical cytometer (HC Plus Cell Control; Coulter Electronics Ltd., Luton, Beds., UK).
Detection oflupus anticoagulant. The presence of lupus anticoagulant was evaluated by the prolongation of APTT in a mixing test (5), adding 1 vol of plasma (whole blood mixed with Na-citrate 0.13 mol/ liter, in a 9:1 ratio), to 1 vol ofactin and incubating for 2 min at 37°C. Another volume of0.02 M CaCl2 was added and the clotting time was recorded in seconds. The presence ofthe lupus anticoagulant was confirmed by the kaolin clotting time (KCT) (5).
Evaluation ofpregnancy outcome. The number of vaginal plugs (indicating mating), the number of pregnancies (indicating fecundity), and the number oflive embryos per successful pregnancy were studied.
Production ofmouse monoclonal anticardiolipin antibodies. 5 mo after immunization with H-3, when constant high levels ofanticardiolipin activity were detected in the sera of the immunized mice, one of the mice was killed and a hybridoma was generated from its splenocytes: the lymphocytes were fused with the NSO mouse myeloma cell line. Out of the many clones obtained, three (CAR 1-3) were chosen because of their ability to bind to cardiolipin, which was confirmed by inhibition assays.
Detection ofthe 16/6 Id in serum and monoclonal antibodies. To determine the presence ofthe 16/6 Id ofanti-DNA antibodies in sera of mice immunized with H-3 and controls and on monoclonal anticardiolipin antibodies (CAR 1-3) we used the ELISA assay employing a specific rabbit anti-16/6 serum. Both methods were detailed previously byus (12, 13 Fig. 1 a. Fig. 1 b shows that the sera also contained antibodies to other phospholipids. The control group, which was immunized with human IgM, exhibited no antiphospholipid activity (Fig. 1, a and b) .
Since the sera ofthe mice also contained anti-ds-DNA antibodies we employed competition assay to determine whether these antibodies are individual antibodies or polyspecific immunoglobulins. Fig. 2 a shows a similar inhibition of binding of the serum to DNA when incubated before the ELISA with cardiolipin (70% inhibition) or DNA (60% inhibition). In contrast, only cardiolipin inhibited (40%) the binding of the serum to cardiolipin, while DNA failed to compete for this binding (Fig. 2 b) . ..-. (Table II) . Similarly, the binding of the sera to platelets could be inhibited by a prior incubation with cardiolipin ( Fig. 2 c) . We failed to demonstrate any binding ofserum immunoglobulins to proteins employing a radioimmunoprecipitation assay (11) with platelet membrane protein (data not shown). A lower fecundity rate was observed in the females immunized with H-3 (21% vs. 48%) (P < 0.005) (Table I) , although there was no decrease in the number of vaginal plugs (indicating mating). Table I shows that a high percentage ofresorptions could be found in the animals immunized with H-3 (25±13 vs. 3±5).
A decrease in the mean (±SD) number oflive embryos was also noted (4.8±2.3) among the mice immunized with anticardiolipin antibody (vs. controls 8±2). Fig. 3 a shows 100% fetal resorption in a representative uterus derived from a mouse immunized with H-3 (top), as compared to a uterus from a nonpregnant mouse (bottom). According to the resorption size we may conclude that the resorption took place in an early gestational stage.
In Fig. 3 b deformed uterus, resorptions, and a low number ofembryos in a mouse immunized with H-3 are depicted com- pared to a normal uterus derived from a mouse immunized with IgM. Observations of placentae of H-3 immunized mice revealed hemorrhages, whereas placentae of an IgM immunized mice contained a bright cap (the decidua) on their surface (data not shown). Using the splenocytes ofone ofthe H-3 immunized mice in the hybridoma technique we generated several monoclonal antibodies with anticardiolipin activity. One of the monoclonal antibodies (CAR-1) was purified and its specific activity to cardiolipin was confirmed using inhibition assays. A 70% inhibition was achieved by preincubating CAR-1 with 100 ,g/ml of cardiolipin. The monoclonal antibody was also shown to have anticoagulant activity, prolonging the APTT of a normal plasma from 36 s up to 80 s when added to the complex (Fig. 4) . The CAR antibody was found to be negative for the 16/6 anti-DNA idiotype.
Discussion
In a previous study (6) we were able to confirm the pathogenicity ofthe anticardiolipin antibodies. Passive transfer of purified serum and monoclonal anticardiolipin antibodies led to the induction of the APLS in mice exemplified by a recurrent fetal loss, thrombocytopenia, and the presence of the serological markers. In our case, immunization with the human ACA (H-3) most probably induced the production of Ab2 (i.e., anti-anticardiolipin) and Ab3 (i.e., anti-anti-anticardiolipin) which practically is the mouse anticardiolipin. From the competition studies it seems that the latter antibodies do cross-react with DNA. Such cross-reactive antibodies were reported in SLE and usually represent antibodies with low avidity to DNA (15, 16 (10, 12, 14, 19, 20) . Previously (19) , we showed the importance of the 16/6 Id in the ability of anti-DNA antibodies to induce experimental SLE with nephritis in mice.
One of the hallmarks of APLS is thrombocytopenia (2) (3) (4) (5) . In our mice we could not find low platelet counts, although in our previous studies with passive transfer ofACA, thrombocytopenia was clearly shown (6) . However, we could confirm the binding ofserum immunoglobulins to platelet's phospholipids. This binding was inhibited by prior incubation with cardiolipin. In contrast the sera did not react with platelet membrane proteins. We have no explanation why thrombocytopenia did not develop, but it is conceivable that a longer follow-up of these mice may disclose this pathology too.
Our induced APLS model shows the ability to induce ACA via idiotypic network employing antibodies with molecular mimicry to the nonimmunogenic molecule ofcardiolipin. The induction actually confirms the pathogenic potential of ACA, shown by us previously following a passive transfer ofACA (6) . In this case the pathogenic ACA were generated de novo by the immunized mice. Last but not least, this model may be employed to determine the efficacy of both preventive measurements as well as novel therapeutic agents.
